Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry

Trial Profile

Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Daclizumab; Peginterferon beta-1a
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TEC-GISTRY
  • Sponsors Biogen
  • Most Recent Events

    • 09 Feb 2017 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2028.
    • 27 Jan 2017 Planned End Date changed from 1 Dec 2023 to 1 Jun 2028.
    • 19 May 2016 The number of treatment arms have been amended from 2 to 3. An additional dalclizumab arm has been added to the treatments.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top